PhaseBio Pharmaceuticals — Investor Presentation (November 2020)
28 slides from PhaseBio Pharmaceuticals's investor presentation, Nov 12, 2020
Slide 1: Corporate Overview November 2020
Corporate Overview November 2020
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”)
Slide 3: Company Overview
Company Overview Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat cardiopulmonary Therapeutic Focus diseases Bentracimab Novel agent in Phase 3 development for immediate and sustained reversal of ticagrelor, the preferred antiplatelet (PB2
Slide 4: A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company
A Clinical Stage, Cardiopulmonary Focused Biopharmaceutical Company Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Bentracimab REVERSE-IT1 Phase 3 ongoing 2H 2020 Reversal of Ticagrelor Targeting to submit BLA in 2H222 Target for publication of Antiplatelet Activit
Slide 5: Corporate
) Corporate
Slide 6: Creating Value for Stakeholders in 2020
Creating Value for Stakeholders in 2020 • Following a successful 2019, PhaseBio continues a rapid pace of development and execution in 2020 Announced innovative funding and co-development collaboration for bentracimab with SFJ Pharmaceuticals Bolstered pipeline with acquisition of resistant hype
Slide 7: Third-Quarter 2020 Financial Highlights
Third-Quarter 2020 Financial Highlights • Operating expense: $20.5M ⎯ R&D: $17.4M ⎯ SG&A: $3.1M • Loss from Operations: ($20.5M) • Net Loss of ($25.1M) or ($0.86) per share ⎯ 29.2M shares used for computing Q3 2020 net loss per share • Cash and cash equivalents as of 09/30/2020: $39.4M 7
Slide 8: Experienced Management Team
Experienced Management Team JONATHAN MOW SUSAN ARNOLD, PhD JIM BALLANCE, PhD GLEN BURKHARDT Chief Executive Officer VP of Preclinical & CMC VP Research & Scientific Affairs VP Human Resources KRIS HANSON JOHN LEE, MD, JOHN SHARP MICHAEL YORK VP Legal PhD, FACC Chief Financial Officer VP Corp Develop
Slide 9: (PB2452) Reversal Agent for Ticagrelor
Bentracimab (PB2452) Reversal Agent for Ticagrelor
Slide 10: Bentracimab: Novel Reversal Agent for Brilinta (Ticagrelor)
Bentracimab Bentracimab: Novel Reversal Agent for Brilinta (Ticagrelor) • Within the P2Y12 antagonist class of oral antiplatelet therapies, ticagrelor has proven superiority vs. clopidogrel, and a unique reversible binding profile ⎯ Clopidogrel and prasugrel, the other members of the oral P2Y12 anta
Slide 11: Bentracimab: Well-Characterized Mechanism of Reversal of Ticagrelor
Bentracimab Bentracimab: Well-Characterized Mechanism of Reversal of Ticagrelor 1. ADP binds to P2Y12 3. Bentracimab binds to free 5. As free ticagrelor is eliminated, ADP can again receptor causing ticagrelor with very high affinity activate the P2Y12 receptor, restoring platelet platelet aggregati
Slide 12: Bentracimab: Development and Regulatory Timelines
Bentracimab Bentracimab: Development and Regulatory Timelines* 2019 2020 2021 2022 2023 NEJM Phase 2a Phase 2b: Older and elderly subjects N=200, 150 randomized to receive bentracimab Breakthrough FDA EMA PRIME Phase 3 interim analysis for Accelerated Approval Post-approval completion of Phase 3 The
Slide 13: Bentracimab Phase 1 Proof-of-Concept Study in Healthy Subjects
Bentracimab Bentracimab Phase 1 Proof-of-Concept Study in Healthy Subjects • Randomized, double-blind, placebo-controlled, single ascending dose, sequential group study (n=64) • Platelet function evaluated using three well established and commonly used assays: LTA, VerifyNow PRUTest® and VASP ⎯ Resu
Slide 14: Normalized Platelet Function After Ticagrelor Reversal
Bentracimab Normalized Platelet Function After Ticagrelor Reversal VerifyNow PRUTest Return to Normal Platelet Normal Platelet Function: Inhibited Platelet Function: Function: Post-Bentracimab Pre-Ticagrelor Dosing Post-Ticagrelor Dosing Dosing Normal Platelet Function Inhibited Platelet Function Pl
Slide 15: Positive Preliminary Bentracimab Phase 2a Results
Bentracimab Positive Preliminary Bentracimab Phase 2a Results • Positive preliminary results from the bentracimab Phase 2a trial were disclosed via press release1 ⎯ First trial of bentracimab to include older and elderly subjects (ages 50-80) on dual antiplatelet therapy (DAPT) of ticagrelor and low
Slide 16: REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview
Bentracimab REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview • REVERSE-IT: Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial • Phase 3 trial is a key element of development plan that has garnered FDA Breakthrough Therapy and EMA PRIME designations • Open-label, single-arm study o
Slide 17: Bentracimab Regulatory Updates
Bentracimab Bentracimab Regulatory Updates Development plan for bentracimab designed with objective to broadly support global regulatory filings Separate written guidance from FDA and EMA indicates that REVERSE-IT, a single, non-randomized, open-label Phase 3 trial of bentracimab in both surgical an
Slide 18: SFJ Pharmaceuticals Funding and Co-Development Collaboration
Bentracimab SFJ Pharmaceuticals Funding and Co-Development Collaboration • Innovative collaboration between SFJ and PhaseBio to support the global development of bentracimab • SFJ will fund up to $120 million to support the clinical development of bentracimab ⎯ SFJ has extensive experience in the gl
Slide 19: Expect Continued Long-Term Rx Growth of Ticagrelor
Bentracimab Expect Continued Long-Term Rx Growth of Ticagrelor Bentracimab approval has the potential to drive continued positive momentum • Brilinta/Brilique sales in 2019 were $1.58B and growing (+20% Y/Y) ⎯ Patient growth drives Y/Y revenue growth in key regions: strong growth in the United State
Slide 20: Pemziviptadil (PB1046) Once Weekly Vasoactive Intestinal Peptide (VIP) Analog
Pemziviptadil (PB1046) Once Weekly Vasoactive Intestinal Peptide (VIP) Analog
Slide 21: Pemziviptadil: Harnessing VIP to Create a Stable, Long-Acting Drug
Pemziviptadil Pemziviptadil: Harnessing VIP to Create a Stable, Long-Acting Drug VIP as a THERAPEUTIC AGENT PRECLINICAL STUDIES Endogenous VIP Pemziviptadil Support Clinical Development for: • Pulmonary Arterial Hypertension • DMD Cardiomyopathy • Heart Failure (Chemotherapy-Induced HF or HFpEF) • C
Slide 22: Proprietary Elastin-Like Polypeptide (ELP) Technology
Pemziviptadil Proprietary Elastin-Like Polypeptide (ELP) Technology Key to optimizing the profile of an injectable VIP product candidate PROLONGED CIRCULATING HALF-LIFE COACERVATION DELIVERS SLOW RELEASE “Biopolymer” Repeating Sequence of Human Elastin Peptides Outside Body Inside Body Active Moiety
Slide 23: High Unmet Need in an Orphan Disease
Pemziviptadil High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) • High unmet need for novel disease-modifying PAH therapies for greater efficacy ⎯ All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways
Slide 24: Pemziviptadil Clinical Development Activities to Date
Pemziviptadil Pemziviptadil Clinical Development Activities to Date Have Supported Advancement into Phase 2 Efficacy Studies PHASE 1 Studies Completed PHASE 2 PAH Studies SAD study in Open-Label Phase 2a CardioMEMS Phase 2b PAH Efficacy hypertensive patients 4-week MAD study in in PAH study: Safety
Slide 25: PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension
PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension
Slide 26: PB6440 for Resistant Hypertension
PB6440 PB6440 for Resistant Hypertension • Upwards of 10 million patients in the United States have resistant hypertension and are at risk for serious, costly medical consequences (stroke, heart attack, kidney failure, etc.)1 • Physicians currently prescribe numerous combinations of antihypertensive
Slide 27: PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2)
PB6440 PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2) Selectivity and Potency Demonstrated in Primate Chronic Oral Dosing Model CYP11B Potency and Selectivity (IC50, µM) Human Monkey CYP11B2 CYP11B1# Selectivity CYP11B2 CYP11B1 Selectivity PB6440 0.024 4.859 202 0.016 5.802 363 LCI699
Slide 28: PhaseBio
PhaseBio
PhaseBio Pharmaceuticals — Investor Presentation (November 2020) on 6ix